{"entity":{"id":"nct07815288","kind":"trial","name":"Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases","aka":[],"tldr":"A phase 2 trial in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.","summary":"Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases is a phase 2, interventional study registered as NCT07815288 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 80 participants, started 2026-09-30 and due to reach its primary completion in 2029-12-30. Interventions recorded: Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy. Conditions listed: Colorectal Adenocarcinoma Metastatic in the Liver. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: \"Histopathologically confirmed colorectal adenocarcinoma; liver metastasis confirmed by pathology or imaging\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07815288","url":"https://clinicaltrials.gov/study/NCT07815288"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07815288","phase":"2","setting":"Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy as Conversion Therapy for Initially Unresectable Colorectal Cancer Liver Metastases: An Exploratory Phase II Study","sponsor":"Peking University Cancer Hospital & Institute","participation":[{"nct":"NCT07815288","source":"https://clinicaltrials.gov/study/NCT07815288","fetchedAt":"2026-10-07T16:56:52.065Z","studySha256":"c2dee14fd686e2cf4aee6c848de54f2810de0a47e848a0245c9e9a5bd334c1a6","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-09-11","leadSponsor":"Peking University Cancer Hospital & Institute","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"79 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":80,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2026-09-30","startedType":"estimated","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07815288/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"},{"id":"immune-exclusion","kind":"term","name":"Immune exclusion","route":"/terms/immune-exclusion/"}]}}